Alliancebernstein L.P. Denali Therapeutics Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 3,137,140 shares of DNLI stock, worth $46.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,137,140
Previous 3,154,387
0.55%
Holding current value
$46.8 Million
Previous $42.9 Million
2.31%
% of portfolio
0.02%
Previous 0.02%
Shares
22 transactions
Others Institutions Holding DNLI
# of Institutions
253Shares Held
135MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$197 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$176 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$173 Million0.13% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$98.2 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$93.4 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...